VISUAL-EVOKED POTENTIALS IN ADRENOLEUKODYSTROPHY - A TRIAL WITH GLYCEROL TRIOLEATE AND LORENZO OIL

被引:39
作者
KAPLAN, PW [1 ]
TUSA, RJ [1 ]
SHANKROFF, J [1 ]
HELLER, J [1 ]
MOSER, HW [1 ]
机构
[1] JOHNS HOPKINS SCH MED,JOHNS HOPKINS HOSP,BALTIMORE,MD
关键词
D O I
10.1002/ana.410340212
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Adrenoleukodystrophy is an X-linked metabolic disorder with very-long-chain fatty acid (VLCFA) accumulation and multifocal nervous system demyelination, often with early involvement of visual pathways. Dietary therapy with glycerol trioleate and glycerol trierucate (Lorenzo oil) diminishes VLCFA levels. In a study of patients with the adrenomyeloneuropathy phenotype of adrenoleukodystrophy, we used pattern-reversal visual evoked potentials to evaluate visual pathways before and after treatment. Of 108 patients tested, all 26 women and 68 of the 82 men had normal potentials at baseline. Seventy patients were retested at 1 year, at which time VLCFA levels were markedly diminished. Of them, the responses in the 10 men who showed abnormalities at baseline remained abnormal; the latencies in 4 men with initially normal responses became abnormal. No patients improved. There were no correlations between disease duration prior to treatment, baseline P100 latencies, VLCFA levels, or the change in P100 latencies and VLCFA levels after dietary treatment for 1 year. Pattern-reversal visual evoked potentials were abnormal in 17% of the men with adrenoleukodystrophy, and there was no evidence that reduction of VLCFA levels improved or retarded visual pathway demyelination.
引用
收藏
页码:169 / 174
页数:6
相关论文
共 39 条
[1]   REVERSAL OF EARLY NEUROLOGIC AND NEURORADIOLOGICAL MANIFESTATIONS OF X-LINKED ADRENOLEUKODYSTROPHY BY BONE-MARROW TRANSPLANTATION [J].
AUBOURG, P ;
BLANCHE, S ;
JAMBAQUE, I ;
ROCCHICCIOLI, F ;
KALIFA, G ;
NAUDSAUDREAU, C ;
ROLLAND, MO ;
DEBRE, M ;
CHAUSSAIN, JL ;
GRISCELLI, C ;
FISCHER, A ;
BOUGNERES, PF .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (26) :1860-1866
[2]   LINKAGE OF ADRENOLEUKODYSTROPHY TO A POLYMORPHIC DNA PROBE [J].
AUBOURG, PR ;
SACK, GH ;
MEYERS, DA ;
LEASE, JJ ;
MOSER, HW .
ANNALS OF NEUROLOGY, 1987, 21 (04) :349-352
[3]   ADRENOLEUKODYSTROPHY - NEUROPHYSIOLOGICAL ASPECTS [J].
BATTAGLIA, A ;
HARDEN, A ;
PAMPIGLIONE, G ;
WALSH, PJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1981, 44 (09) :781-785
[4]  
Blaw M, 1970, HDB CLIN NEUROLOGY, V10, P128
[5]  
CHIAPPA KH, 1989, EVOKED POTENTIALS CL, P111
[6]  
COHEN SMZ, 1983, AM J OPHTHALMOL, V95, P82
[7]   ADRENOLEUKODYSTROPHY AND VARIANTS - CLINICAL, NEUROPHYSIOLOGICAL AND BIOCHEMICAL-STUDIES IN PATIENTS AND FAMILY MEMBERS [J].
GOTO, I ;
KOBAYASHI, T ;
ANTOKU, Y ;
TOBIMATSU, S ;
KUROIWA, Y .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1986, 72 (01) :103-112
[8]   ADRENOMYELONEUROPATHY - PROBABLE VARIANT OF ADRENOLEUKODYSTROPHY .1. CLINICAL AND ENDOCRINOLOGIC ASPECTS [J].
GRIFFIN, JW ;
GOREN, E ;
SCHAUMBURG, H ;
ENGEL, WK ;
LORIAUX, L .
NEUROLOGY, 1977, 27 (12) :1107-1113
[9]   EVOKED-POTENTIALS IN ASSESSMENT AND FOLLOW-UP OF PATIENTS WITH WILSONS-DISEASE [J].
GRIMM, G ;
ODER, W ;
PRAYER, L ;
FERENCI, P ;
MADL, C .
LANCET, 1990, 336 (8721) :963-964
[10]   FATTY-ACID ABNORMALITY IN ADRENOLEUKODYSTROPHY [J].
IGARASHI, M ;
SCHAUMBURG, HH ;
POWERS, J ;
KISHIMOTO, Y ;
KOLODNY, E ;
SUZUKI, K .
JOURNAL OF NEUROCHEMISTRY, 1976, 26 (04) :851-&